A tumour-suppressive relationship between these nuclear receptors was illustrated by co-treatment with mineralocorticoids and retinoic acid receptor-stimulating retinoids [163], highlighting another potential therapeutic pathway worth characterising in the setting of breast cancer resistant to standard ER-targeted therapies. The gene discussed is ESR1; the disease is breast cancer.